Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 mediator kinase inhibition
Year: 2026
Type: article
Abstract: Anoikis resistance or evasion of cell death triggered by cell detachment into suspension is a hallmark of cancer that is concurrent with cell survival and metastasis. The effects of frequent matrix detachment encounters on the development of anoikis resistance in cancer remains poorly defined. Here we show using a panel of ovarian cancer models, that repeated exposure to suspension stress in vitro followed by attached recovery growth leads to the development of anoikis resistance paralleling in vivo development of anoikis resistance in ovarian cancer ascites. This resistance is concurrent with enhanced invasion, chemoresistance and the ability of anoikis adapted cells to metastasize to distant sites. Adapted anoikis resistant cells show a heightened dependency on oxidative phosphorylation and can also evade immune surveillance. We find that such acquired anoikis resistance is not genetic, as acquired resistance persists for a finite duration in the absence of suspension stress. Transcriptional reprogramming is however essential to this process, as acquisition of adaptive anoikis resistance in vitro and in vivo is exquisitely sensitive to inhibition of CDK8/19 Mediator kinase, a pleiotropic regulator of transcriptional reprogramming. Our data demonstrate that growth after recovery from repeated exposure to suspension stress is a direct contributor to metastasis and that inhibition of CDK8/19 Mediator kinase during such adaptation provides a therapeutic opportunity to prevent both local and distant metastasis in cancer.
Source: JCI Insight
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,100
Funders: University of South Carolina, National Institutes of Health, University of Texas MD Anderson Cancer Center, Center for AIDS Research, University of Washington, Nutrition Obesity Research Center, University of North Carolina, National Cancer Institute, National Institute of General Medical Sciences, National Institute of Diabetes and Digestive and Kidney Diseases
Awards: G1406628966, Lumina III System for UAB Optical Imaging, Center for Clinical and Translational Science, Center for Targeted Therapeutics, G4481712008, G8247680792, G8574385681, G860149444, G8719566466, Preventing in vivo resistance to PI3K/AKT/mTOR inhibitors through Mediator kinase inhibition, G9000046622, G9000059695, G9000120957, G9000128834, G9000221784, G9000343736, Preventing adaptive drug resistance through Mediator kinase inhibition, G94475886
OpenAlex ID: W7124310400
